


Benefit from ETA-Guided Therapies

Stage IV Ovarian Cancer. 48 year old female patient.
Cancer had progressed following **3** lines of therapy.

PFS
337 days

Tumor Hallmarks

GNAS SNV
TP53 SNV
KRAS SNV
EGFR SNV
ALK SNV



Baseline


Follow-Up

Regimen

Agent	Indication	Starting Dose
IV Cyclophosphamide	Chemosensitivity	1500 mg / 21D
Tab Etoposide	Chemosensitivity	50 mg, 1 OD
Tab Methotrexate	Chemosensitivity	2.5 mg / 7D

Benefit from ETA-Guided Therapies

Stage IV Breast Cancer. 53 year old female patient.
Cancer had progressed following **10** lines of therapy.



Tumor Hallmarks

FGFR1 CNV+
SRC CNV+
CDK4 CNV+
ESR1 SNV
PARP1 SNV
TUBB3 Overexpression
TOP2A Overexpression

PFS

166 days

Regimen		
Agent	Indication	Starting Dose
Tab Dasatinib	FGFR1	50 mg / 1 OD
Inj Temezirolimus	Chemosensitivity	25 mg / 14D